Abiopharma

🔍 Lizzul Paul F. (Executive)

Company: ANAPTYSBIO, INC (ANAB)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 8,525 shares of Common Stock (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,738.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,650 shares of Common Stock at $44.71 per share (Direct)
  Date: 2026-01-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 42,088.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 8,525 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 25,575.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
• F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.